2 assets in Rectum Malignant Melanoma

Therapeutic assets addressing Rectum Malignant Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Rectum Malignant Melanoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Rectum Malignant Melanoma	National Cancer Institute (NCI)	P2	CCC (53)